Medera in the News

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

October 31, 2024

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

September 24, 2024

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

September 5, 2024

Medera’s Sardocor Showcases Positive Interim Data from HErEF Gene Therapy Phase 1/2 Clinical Trial in Late-Breaking Oral Presentation at 27th Annual Meeting of American Society of Gene and Cell Therapy

May 6, 2024

Medera’s Sardocor Granted FDA Orphan Drug Designation for DMD-associated cardiomyopathy Gene Therapy

February 28, 2024

Medera's Sardocor announces fast track designation and dosing of 3 patients in first-in-human HFpEF gene therapy trial

February 14, 2024

Heart-in-a-jar: Singapore to bioengineer Asian mini models of failed hearts to test drugs

December 6, 2023

Medera's Sardocor announces FDA clearance of IND for first-in-human gene therapy clinical trial for DMD cardiomyopathy

December 01, 2022

Medera receives FDA clearance for first-in-human gene therapy for heart failure with preserved ejection fraction

November 18, 2022

Medera’s Novoheart partners with AstraZeneca on First Bioengineered Human Models of Heart Failure

October 27, 2022

3D-printed mini-organs may provide safe testing of COVID-19 therapies

May 12, 2020

Heart-In-A-Jar Platform Humanizing Preclinical Research

January 6, 2020